Du, G.; Emtenani, S.; Niese, D.; Liu, J.; Gebauer, F.; Dunst, N.J.; Gökce, A.; Spaniol, K.; Groeber-Becker, F.; Šimunović, J.;
et al. Complement Activation May Drive the Pathogenicity of Anti-α6 and Anti-β4 Integrin Antibodies In Vivo. Biomolecules 2026, 16, 417.
https://doi.org/10.3390/biom16030417
AMA Style
Du G, Emtenani S, Niese D, Liu J, Gebauer F, Dunst NJ, Gökce A, Spaniol K, Groeber-Becker F, Šimunović J,
et al. Complement Activation May Drive the Pathogenicity of Anti-α6 and Anti-β4 Integrin Antibodies In Vivo. Biomolecules. 2026; 16(3):417.
https://doi.org/10.3390/biom16030417
Chicago/Turabian Style
Du, Gefei, Shirin Emtenani, Dennis Niese, Jian Liu, Ferdinand Gebauer, Neele J. Dunst, Aysun Gökce, Kristina Spaniol, Florian Groeber-Becker, Jelena Šimunović,
and et al. 2026. "Complement Activation May Drive the Pathogenicity of Anti-α6 and Anti-β4 Integrin Antibodies In Vivo" Biomolecules 16, no. 3: 417.
https://doi.org/10.3390/biom16030417
APA Style
Du, G., Emtenani, S., Niese, D., Liu, J., Gebauer, F., Dunst, N. J., Gökce, A., Spaniol, K., Groeber-Becker, F., Šimunović, J., Novokmet, M., Geerling, G., Amber, K. T., Hoffmann, M. H., Ludwig, R. J., Bieber, K., Goletz, S., Zhou, G., Schmidt, E.,
& Patzelt, S.
(2026). Complement Activation May Drive the Pathogenicity of Anti-α6 and Anti-β4 Integrin Antibodies In Vivo. Biomolecules, 16(3), 417.
https://doi.org/10.3390/biom16030417
